AstraZeneca will collaborate with Accent Therapeutics to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins (RMPs) for the treatment of cancer. This collaboration focuses on targeting RMPs, proteins that control many aspects of RNA biology and represeAlready a subscriber Login You have read all your free articles, to continue…